{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:48:27Z","timestamp":1790401707104,"version":"4.1.0"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":445,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T00:00:00Z","timestamp":1726444800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Benefits of mineralocorticoid receptor antagonists (MRAs) in heart failure with preserved and mildly reduced ejection fraction (HFpEF\/HFmrEF) have not been established. Conventional randomized controlled trials are complex and expensive. The Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure with Preserved Ejection Fraction (SPIRRIT-HFpEF) is a unique pragmatic registry-based randomized controlled trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>SPIRRIT-HFpEF is a multicentre, prospective, randomized, open-label, blinded endpoint trial conducted on platforms in the Swedish Heart Failure Registry (SwedeHF) and the United States (US) Trial Innovation Network. Patients with HFpEF\/HFmrEF are randomized 1:1 to spironolactone (or eplerenone) in addition to usual care, versus usual care alone. The primary outcome is total number of cardiovascular deaths and hospitalizations for heart failure. Outcomes are collected from Swedish administrative complete coverage registries and a US call centre and subsequently adjudicated. Simple eligibility criteria were based on data available in SwedeHF: heart failure as outpatient or at discharge from hospital, left ventricular ejection fraction \u226540%, N-terminal pro-B-type natriuretic peptide &amp;gt;300\u2009ng\/L (in sinus rhythm) or\u2009&amp;gt;750\u2009ng\/L (in atrial fibrillation), with pre-specified adjustment for elevated body mass index, and chronic loop diuretic use. Power and sample size assessments were based on an event-driven design allowing enrolment over approximately 6\u2009years, and application of hazard ratios from the TOPCAT trial, Americas subset. The final sample size is expected to be approximately 2400 patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>SPIRRIT-HFpEF will be informative on the effectiveness of generic MRAs in HFpEF and HFmrEF, and on the feasibility of conducting pragmatic and registry-based trials in heart failure and other chronic conditions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ejhf.3453","type":"journal-article","created":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T06:34:55Z","timestamp":1726468495000},"page":"2453-2463","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["The Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure with Preserved Ejection Fraction (SPIRRIT-HFpEF): Rationale and Design"],"prefix":"10.1093","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1411-4482","authenticated-orcid":false,"given":"Lars H.","family":"Lund","sequence":"first","affiliation":[{"name":"Department of Medicine, Karolinska Institutet \u00a0","place":["Sweden"]},{"name":"Department of Cardiology, Karolinska University Hospital , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"James","sequence":"additional","affiliation":[{"name":"Uppsala Clinical Research Center and Department of Medical Sciences, Cardiology, Uppsala University , Uppsala ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam D.","family":"DeVore","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University School of Medicine , Durham, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin J.","family":"Anstrom","sequence":"additional","affiliation":[{"name":"Collaborative Studies Coordinating Center, Department of Biostatistics, University of North Carolina at Chapel Hill , Chapel Hill, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marat","family":"Fudim","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University School of Medicine , Durham, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith D.","family":"Aaronson","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan , Ann Arbor, MI ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"Dahlstr\u00f6m","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Linkoping University , Linkoping ,","place":["Sweden"]},{"name":"Department of Health, Medicine and Caring Sciences, Linkoping University , Linkoping ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Desvigne-Nickens","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute , Bethesda, MD ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome L.","family":"Fleg","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute , Bethesda, MD ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Yang","sequence":"additional","affiliation":[{"name":"Division of Intramural Research, National Heart, Lung, and Blood Institute , Bethesda, MD ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Fu","sequence":"additional","affiliation":[{"name":"Sahlgrenska Academy and University of Gothenburg , G\u00f6teborg ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Hage","sequence":"additional","affiliation":[{"name":"Department of Medicine, Karolinska Institutet \u00a0","place":["Sweden"]},{"name":"Department of Cardiology, Karolinska University Hospital , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claes","family":"Held","sequence":"additional","affiliation":[{"name":"Uppsala Clinical Research Center and Department of Medical Sciences, Cardiology, Uppsala University , Uppsala ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patric","family":"Karlstr\u00f6m","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Linkoping University , Linkoping ,","place":["Sweden"]},{"name":"Department of Health, Medicine and Caring Sciences, Linkoping University , Linkoping ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Nygren","sequence":"additional","affiliation":[{"name":"Department of Medicine, Karolinska Institutet \u00a0","place":["Sweden"]},{"name":"Department of Cardiology, Karolinska University Hospital , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric D.","family":"Peterson","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Texas Southwestern Medical Center , Dallas, TX ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tymon","family":"Pol","sequence":"additional","affiliation":[{"name":"Uppsala Clinical Research Center and Department of Medical Sciences, Cardiology, Uppsala University , Uppsala ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelly","family":"Sapp","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University School of Medicine , Durham, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Sundstr\u00f6m","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Uppsala University , Uppsala ,","place":["Sweden"]},{"name":"The George Institute for Global Health, University of New South Wales , Sydney, NSW ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ollie","family":"\u00d6stlund","sequence":"additional","affiliation":[{"name":"Uppsala Clinical Research Center and Department of Medical Sciences, Cardiology, Uppsala University , Uppsala ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Oldgren","sequence":"additional","affiliation":[{"name":"Uppsala Clinical Research Center and Department of Medical Sciences, Cardiology, Uppsala University , Uppsala ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertram","family":"Pitt","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan , Ann Arbor, MI ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,9,16]]},"reference":[{"key":"2026010913045471700_ejhf3453-bib-0001","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/ejhf.2333","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"24","author":"McDonagh","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026010913045471700_ejhf3453-bib-0002","doi-asserted-by":"crossref","first-page":"7","DOI":"10.15420\/cfr.2016:25:2","article-title":"Global public health burden of heart failure","volume":"3","author":"Savarese","year":"2017","journal-title":"Card Fail Rev"},{"key":"2026010913045471700_ejhf3453-bib-0003","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s41569-021-00605-5","article-title":"Heart failure with mid-range or mildly reduced ejection fraction","volume":"19","author":"Savarese","year":"2022","journal-title":"Nat Rev Cardiol"},{"key":"2026010913045471700_ejhf3453-bib-0004","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1093\/eurheartj\/ehac248","article-title":"An update on global epidemiology in heart failure","volume":"43","author":"Becher","year":"2022","journal-title":"Eur Heart J"},{"key":"2026010913045471700_ejhf3453-bib-0005","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A novel paradigm for heart failure with preserved ejection fraction: Comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation","volume":"62","author":"Paulus","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026010913045471700_ejhf3453-bib-0006","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1093\/eurheartj\/ehy531","article-title":"Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEF","volume":"39","author":"Shah","year":"2018","journal-title":"Eur Heart J"},{"key":"2026010913045471700_ejhf3453-bib-0007","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41572-024-00540-y","article-title":"Heart failure with preserved ejection fraction","volume":"10","author":"Hamo","year":"2024","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"2026010913045471700_ejhf3453-bib-0008","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"issue":"16","key":"2026010913045471700_ejhf3453-bib-0009","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"issue":"12","key":"2026010913045471700_ejhf3453-bib-0010","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"issue":"15","key":"2026010913045471700_ejhf3453-bib-0011","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"key":"2026010913045471700_ejhf3453-bib-0012","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","article-title":"Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial","volume":"131","author":"Pfeffer","year":"2015","journal-title":"Circulation"},{"key":"2026010913045471700_ejhf3453-bib-0013","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1002\/ejhf.621","article-title":"A tentative interpretation of the TOPCAT trial based on randomized evidence from the brain natriuretic peptide stratum analysis","volume":"18","author":"Girerd","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026010913045471700_ejhf3453-bib-0014","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/ejhf.3253","article-title":"Finerenone in patients with heart failure with mildly reduced or preserved ejection fraction: Rationale and design of the FINEARTS-HF trial","volume":"26","author":"Vaduganathan","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026010913045471700_ejhf3453-bib-0015","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1001\/jama.2013.905","article-title":"Aldo-DHF Investigators. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial","volume":"309","author":"Edelmann","year":"2013","journal-title":"JAMA"},{"issue":"2","key":"2026010913045471700_ejhf3453-bib-0016","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11897-017-0325-0","article-title":"Registry-based pragmatic trials in heart failure: Current experience and future directions","volume":"14","author":"Lund","year":"2017","journal-title":"Curr Heart Fail Rep"},{"key":"2026010913045471700_ejhf3453-bib-0017","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.1093\/eurheartj\/ehac400","article-title":"Pragmatism in clinical trials: Essential, not optional","volume":"43","author":"Usman","year":"2022","journal-title":"Eur Heart J"},{"key":"2026010913045471700_ejhf3453-bib-0018","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.jclinepi.2008.12.011","article-title":"A pragmatic-explanatory continuum indicator summary (PRECIS): A tool to help trial designers","volume":"62","author":"Thorpe","year":"2009","journal-title":"J Clin Epidemiol"},{"key":"2026010913045471700_ejhf3453-bib-0019","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S0735-1097(99)00027-3","article-title":"A view from the millennium: The practice of cardiology circa 1950 and thereafter","volume":"33","author":"Silverman","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"2026010913045471700_ejhf3453-bib-0020","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1002\/ejhf.2338","article-title":"Phenotyping heart failure patients for iron deficiency and use of intravenous iron therapy: Data from the Swedish Heart Failure Registry","volume":"23","author":"Becher","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026010913045471700_ejhf3453-bib-0021","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1080\/03009734.2018.1490831","article-title":"The Swedish Heart Failure Registry: A living, ongoing quality assurance and research in heart failure","volume":"124","author":"Savarese","year":"2019","journal-title":"Ups J Med Sci"},{"key":"2026010913045471700_ejhf3453-bib-0022","doi-asserted-by":"crossref","first-page":"4257","DOI":"10.1093\/eurheartj\/ehy621","article-title":"Association between renin-angiotensin system inhibitor use and mortality\/morbidity in elderly patients with heart failure with reduced ejection fraction: A prospective propensity score-matched cohort study","volume":"39","author":"Savarese","year":"2018","journal-title":"Eur Heart J"},{"key":"2026010913045471700_ejhf3453-bib-0023","volume-title":"SWEDEHEART Annual Report 2021","author":"Swedish Heart Failure Registry","year":"2022"},{"key":"2026010913045471700_ejhf3453-bib-0024","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.cardfail.2019.04.013","article-title":"Do patients with acute heart failure and preserved ejection fraction have heart failure at follow-up: Implications of the Framingham criteria","volume":"26","author":"Hage","year":"2020","journal-title":"J Card Fail"},{"key":"2026010913045471700_ejhf3453-bib-0025","first-page":"201","article-title":"Oxygen therapy in suspected acute myocardial infarction","volume":"378","author":"Hofmann","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"2026010913045471700_ejhf3453-bib-0026","first-page":"300","article-title":"Bivalirudin versus heparin monotherapy in myocardial infarction","volume":"378","author":"Erlinge","year":"2018","journal-title":"N Engl J Med"},{"key":"2026010913045471700_ejhf3453-bib-0027","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/ejhf.29","article-title":"Analysing recurrent hospitalizations in heart failure: A review of statistical methodology, with application to CHARM-Preserved","volume":"16","author":"Rogers","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"2026010913045471700_ejhf3453-bib-0028","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1161\/CIRCULATIONAHA.117.033065","article-title":"Comparison of time-to-first event and recurrent-event methods in randomized clinical trials","volume":"138","author":"Claggett","year":"2018","journal-title":"Circulation"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/26\/11\/2453\/65507824\/eurjhf_26_11_2453.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/26\/11\/2453\/65507824\/eurjhf_26_11_2453.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T18:05:38Z","timestamp":1767981938000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/26\/11\/2453\/8328641"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,16]]},"references-count":28,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,9,16]]},"published-print":{"date-parts":[[2024,11,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.3453","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,11]]},"published":{"date-parts":[[2024,9,16]]},"assertion":[{"value":"2024-08-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}